Jason Gardner

Pioneer
DISC Type : ids

CEO at Ampersand Biomedicines

Cambridge, Massachusetts, United States

Overview

Jason is a seasoned biotech leader with over two decades of experience, currently serving as CEO-Partner at Flagship Pioneering and CEO of Ampersand Biomedicines. He previously co-founded and led Magenta Therapeutics through a successful IPO. His career includes extensive leadership at GSK, informed by a D. Phil. from Oxford University and a postdoctoral fellowship at Harvard University.

He created and led the Regenerative Medicine Unit at GSK, which established partnerships that led to the approval of one of the first stem cell gene therapies.

Personality Overview

Decisive But Friendly

Dynamic But Sincere

Friendly But Fast

They combine a unique set of diverse traits where they are fast and friendly but can slow down to be thorough when needed  They have the unique ability to win both love and respect from their team (or outsiders) If they are convinced, they can become very strong champions for your product

Topics They Care About

Platform-based Medicines
Currently leading Ampersand Biomedicines, which focuses on a platform to create smarter medicines that act specifically at the site of disease, which he calls a "molecular FedEx".
Biotech Venture Building
Has a strong track record of creating and scaling companies, from being an Entrepreneur-in-Residence to co-founding Magenta Therapeutics and now acting as CEO-Partner at Flagship Pioneering.
Stem Cell Therapies
A core area of his expertise, having co-founded Magenta Therapeutics to revolutionize stem cell transplantation and having previously established GSK's stem cell gene therapy programs.

Media Appearances

Precision Drug Delivery with Ampersand Biomedicines' Jason Gardner. Featured in Apple Podcasts

See Now

2025 CEO Chat: Jason Gardner, CEO of Ampersand Biomedicines. Featured in YouTube

See Now

Jason Gardner: From GSK To Ampersand Biomedicines CEO. Featured in YouTube

See Now

Work History

8-2023
CEO at Ampersand Biomedicines
8-2023
CEO-Partner at Flagship Pioneering
6-2017 - 4-2024
Independent Board Director at Obsidian Therapeutics
11-2016 - 2-2023
CEO, President and Cofounder at Magenta Therapeutics
11-2015 - 11-2016
Enrepeneur-in-Residence at Atlas Venture

Education

1995 - 1997
Post Doctoral Fellowship from Harvard University
1991 - 1995
Doctor of Philosophy (Ph.D.) from University of Oxford

More Information

Social Presence :

Prographics :

Exp : 10 Location : Cambridge, Massachusetts, United States Job Level : Leadership Designation : CEO at Ampersand Biomedicines
URL has been copied!

Insights For Selling To Jason

During A Call Or A Meeting

DO's

  • Keep your pitch focused on the impact but nurture the relationship too
  • Use phrases like ‘your decision will’, ‘you will impact’ etc.
  • Mostly stick to your standard pitch and qualifying script, but add some stories or anecdotes to it

DONT's

  • Don’t be very informal during the early interactions even if they are being so themselves
  • Don’t hesitate from asking questions or pushing them, but take a formal approach
  • Don't lean very heavily into providing too much information, sharing whitepapers etc.

When Cold Calling

When Writing An Email

While Negotiating & Closing

    The secret to closing fast with Jason is

  • Nothing less than a strong combination of proof of results, relationship and high levels of professionalism is effective with them.
  • Will you ever get a clear answer from Jason

  • They can say no while staying friendly, but can also be pursuaded to reconsider

Insights For Deal Planning

    How fast (or slow) will Jason move?

  • They are generally fast movers and can take quick decisions
  • Can Jason take some risk or not?

  • They have high risk-appetite but can get ahead of themselves once in a while. Observe carefully

You And Jason

Personality Compatibility


More Profiles

Discover additional public profiles from our index.

Search more profiles

Looking for someone else? Search here for anyone.

Or visit Humantic AI to know more.